

## Interview with LIDDS's Chairman of the Board published on the company's website

**UPPSALA SWEDEN - LIDDS announces today that an interview with Chairman Pontus Ottosson has been published on the company's website.**

Pontus Ottosson was elected Chairman at the Annual General Meeting May 29, 2023. In an interview, published today on the company's website, he summarizes his view on the company's situation and the way forward.

"I know the company's background and technology and think that there are a number of interesting assets in the company. I have personally been an investor and shareholder in the company since 2003. I also know the importance of daring to be proactive when required, honest in one's analysis and able to stick to one's strategies to make companies succeed over time. Sometimes these decisions are uncomfortable and can lead to short-term turmoil, but are absolutely necessary for long-term success. My firm belief is that LIDDS's technology, projects and patents have a significantly greater value than what the share price today reflects, the challenge is to realize these values in a way that is as good as possible for the company and its shareholders" says Pontus Ottosson. The full interview, in Swedish, can be read at <https://liddspharma.com/sv/intervju-pontus-ottosson/>.

**For additional information, please contact**

---

Anders Månsson, CEO  
Phone: +46 (0)70 860 47 38  
E-mail: [anders.mansson@liddspharma.com](mailto:anders.mansson@liddspharma.com)

Jenni Björnulfson, CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS's Certified Adviser is Redeye AB

**LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

## **Attachments**

---

**Interview with LIDDS's Chairman of the Board published on the company's website**